REZLIDHIA (olutasidenib)
Relapsed or Refractory Acute Myeloid Leukemia (AML) with susceptible IDH1 mutation
ApprovedCommercial
Key Facts
Indication
Relapsed or Refractory Acute Myeloid Leukemia (AML) with susceptible IDH1 mutation
Phase
Approved
Status
Commercial
Company
About Rigel Pharmaceuticals
Rigel Pharmaceuticals is a commercial-stage biotech with a strategic focus on hematology and oncology, building a portfolio of approved and investigational therapies. The company has successfully brought multiple products to market, including TAVALISSE for ITP and REZLIDHIA for AML, and is advancing a pipeline through both internal R&D and strategic collaborations, such as its partnership with Eli Lilly on a RIPK1 inhibitor. Headquartered in South San Francisco, Rigel operates as a public company (NASDAQ: RIGL) and is led by a seasoned management team with deep experience in biopharma development and commercialization.
View full company profile